Central Pharmaceutical Joint Stock Co No2
UUPCOM:DP24,900.00
VND
+400.00
(+8.89%)
ISIN
VN000000DP28
Return %
Stock
S&P 500
1Y
6.52
14.20
3Y
22.50
81.12
5Y
-22.22
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- Address
- IPO Date
- May 19, 2017
- Similar Companies
- Business
- Central Pharmaceutical Joint Stock Company No. 2, operating under the trade name DOPHARMA (UPCoM: DP2), is a Vietnam-based pharmaceutical enterprise primarily engaged in the research, manufacturing, trading, and distribution of finished pharmaceuticals, traditional medicines, medical equipment, and healthcare products. The company's core product portfolio encompasses a broad spectrum of prescription and over-the-counter (OTC) pharmaceutical products across multiple therapeutic categories, including anti-infective and antibacterial agents, such as beta-lactam antibiotics, cephalosporins, aminoglycosides, phenicols, and nitroimidazoles; cardiovascular drugs for the management of hypertension, heart failure, and hyperlipidemia; analgesic, antipyretic, and anti-inflammatory medications, marketed under commercial brand lines such as Topsea and Calmezin; gastrointestinal formulations, including antacids, anti-ulcer therapies, antiemetics, and laxatives; vitamin and mineral supplements, including TIDICOBA (vitamin B-complex formulations), high-potency Vitamin E soft capsules, and Ferimax; oncology and immunomodulatory agents; dermatological treatments; and traditional herbal medicines, medicated liniments, and essential oil-based balms. DOPHARMA manufactures these therapeutics in diverse dosage forms, comprising sterile powder for injections, soft gelatin capsules, compressed tablets, oral syrups, suspensions, and topical solutions. Beyond finished dosage formulation, the company engages in the wholesale and distribution of active pharmaceutical ingredients (APIs), pharmaceutical raw materials, medicinal herbs, chemical reagents, medical instruments, and specialized pharmaceutical packaging materials, while also providing pharmaceutical technology transfer and technical consulting services. Originally established in 1947 as a military pharmaceutical workshop and formally organized under the Ministry of Health as Central Pharmaceutical Enterprise No. 2 in 1960, the enterprise was equitized into a joint stock company in 2004, commenced operations under its current corporate structure in 2005, and listed its shares on the UPCoM exchange in May 2017. The company is headquartered in Hanoi, Vietnam, and operates a production complex meeting Good Manufacturing Practice standards set by the World Health Organization (GMP-WHO) located in the Quang Minh Industrial Park, Me Linh District, Hanoi, serving hospitals, clinics, medical centers, and pharmacy chains throughout Vietnam, with strategic shareholding participation from Vietnam National Pharmaceutical Joint Stock Company (Vinapharm) and Saigon Handicraft Import-Export Joint Stock Company. In recent developments over the past one to two years, Central Pharmaceutical Joint Stock Company No. 2 has undertaken extensive operational and financial restructuring to counter inflationary pressures on active ingredient costs and high debt-servicing expenses tied to its plant capital investments. The company has implemented production rationalization measures at its Quang Minh manufacturing facility, streamlined its product mix to prioritize high-margin oral and injectable therapeutics, engaged in successful debt and interest-relief negotiations with commercial banking partners to stabilize working capital, and revised its strategic commercial targets at recent general shareholder meetings to enhance domestic distribution efficiency and supply-chain resilience.